Bioorganic & Medicinal Chemistry Letters 18 (2008) 4447

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier.com/locate/bmcl

Erratum

Erratum to ``Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors" [Bioorg. Med. Chem. Lett. 18 (2008) 3236­3241]
J. N. Cumming a,*, T. X. Le b,*, S. Babu b, C. Carroll b, X. Chen a, L. Favreau a, P. Gaspari b, T. Guo b, D. W. Hobbs b, Y. Huang a, U. Iserloh a, M. E. Kennedy a, R. Kuvelkar a, G. Li a, J. Lowrie b, N. A. McHugh a, L. Ozgur b, J. Pan a, E. M. Parker a, K. Saionz b, A. W. Stamford a, C. Strickland a, D. Tadesse b, J. Voigt a, L. Wang a, Y. Wu a, L. Zhang a, Q. Zhang a
a b

Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543, USA

The publisher regrets that the author and affiliation lines are incorrect as they appear in the printed issue. The correct author and affiliation lines are shown above.

DOI of original article: 10.1016/j.bmcl.2008.04.050 * Corresponding authors. Tel.: +1 908 740 2515; fax: +1 908 740 7152 (J.N. Cumming); tel.: +1 609 452 3674; fax: +1 609 655 4187 (T.X. Le). E-mail addresses: jared.cumming@spcorp.com (J.N. Cumming), tle@pcop.com (T.X. Le). 0960-894X/$ - see front matter Ó 2008 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2008.06.022

